Session 12 - CROI 2007

Session 12 Oral Abstracts
Metabolic and Cardiovascular Complications of ART
Monday, 10 am - 12:15 pm
Room: Petree Hall

10:00 am 37	HIV-related Immune Suppression after ART Predicts Risk of Non-opportunistic Diseases: Results from the FIRST Study Jason Baker^1,2, Jason Baker^1,2, G Peng¹, J Rapkin¹, D Abrams³, M Silverberg⁴, W Cavert¹, R MacArthur⁵, W Henry^1,2, W Henry^1,2, J Neaton¹, and Terry Beirn Community Prgms for Clin Res on AIDS (CPCRA) ¹Univ of Minnesota, Minneapolis, US; ²Hennepin County Med Ctr, Minneapolis, MN, US; ³Univ of California, San Francisco, US; ⁴Kaiser Permanente, Oakland, CA, US; and ⁵Wayne State Univ, Detroit, MI, US
10:15 am 38	Metabolic Outcomes of ACTG 5142: A Prospective, Randomized, Phase III Trial of NRTI-, PI-, and NNRTI-sparing Regimens for Initial Treatment of HIV-1 Infection Richard H. Haubrich*¹, S Riddler², G DiRienzo³, L Komarow³, W Powderly⁴, K Garren⁵, T George⁶, J Rooney⁷, J Mellors², D Havlir⁸, and the AIDS Clinical Trials Group 5142 Study Team ¹Univ of California, San Diego, US; ²Univ of Pittsburgh, PA, US; ³Harvard Sch of Publ Hlth, Statistical and Data Analysis Ctr, Boston, MA, US; ⁴Univ Coll Dublin, Ireland; ⁵Abbott Labs, Abbott Park, IL, US; ⁶Bristol-Myers Squibb, Plainsboro, NJ, US; ⁷Gilead Sci, Foster City, CA, US; and ⁸Univ of California, San Francisco, US
10:30 am 39	Ezetimibe’s Effects on the LDL Cholesterol Levels of HIV-infected Patients Receiving HAART David Wohl*¹, P Hsue², S Richard¹, A Schnell², S Napravnik¹, R Simpson¹, J Keys¹, and D Waters² ¹Univ of North Carolina at Chapel Hill, US and ²Univ of California, San Francisco, US
10:45 am 40	Poly-L-lactic Acid Injections for Facial Lipoatrophy: A Randomized, Multicenter Trial Dianne Carey*¹, D Baker², N Easey³, K Petoumenos¹, S Emery¹, J Chuah⁴, K Machon⁵, G Rogers⁶, D Cooper^1,3, D Cooper^1,3, A Carr³, and for the Facial Lipoatrophy Study in HIV (FLASH) Investigators ¹Natl Ctr for HIV Epidemiology and Clin Res, Univ of New South Wales, Australia; ²407 Doctors, Sydney, Australia; ³St Vincent's Hosp, Sydney, Australia; ⁴Gold Coast Sexual Hlth Clin, Miami, Australia; ⁵Natl Assn of People with HIV/AIDS, Sydney, Australia; and ⁶Secretariat of the Pacific Community, Noumea, New Caledonia
11:00 am 41	Interruption of ART and Risk of Cardiovascular Disease: Findings from SMART Andrew Phillips*¹, A Carr², J Neuhaus¹, F Visnegarwala³, R Prineas⁴, W Burman⁵, I Williams⁶, F Drummond⁷, D Duprez¹, J Lundgren⁸, and others for the SMART Study Group ¹Univ of Minnesota, Minneapolis, US; ²St Vincent's Hosp, Univ New South Wales, Sydney, Australia; ³Baylor Coll of Med, Houston, TX, US; ⁴Univ of Wake Forest Sch of Med, Winston-Salem, NC, US; ⁵Denver Publ Hlth, CO, US; ⁶Royal Free and Univ Coll London Med Sch, UK; ⁷Natl Ctr for HIV Epidemiology and Clin Res, Sydney, Australia; and ⁸Hvidovre Hosp, Copenhagen, Denmark
11:15 am 42	Alendronate with Calcium and Vitamin D Supplementation Is Superior to Calcium and Vitamin D Alone in the Management of Decreased Bone Mineral Density in HIV-infected patients: Results of ACTG 5163 Grace A McComsey*¹, M Kendall², P Tebas³, S Swindells⁴, E Hogg⁵, B Alston-Smith⁶, C Suckow⁷, G Gopalakrishnan⁸, C Benson⁹, D Wohl¹⁰, and AIDS Clinical Trials Group ACTG 5163 ¹Case Western Reserve Univ, Cleveland, OH, US; ²Statistical & Data Analysis Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; ³Univ of Pennsylvania, Philadelphia, US; ⁴Univ of Nebraska Med Ctr, Omaha, US; ⁵Social & Sci Systems, Silver Spring, MD, US; ⁶NIAID, NIH, Bethesda, MD, US; ⁷Frontier Sci & Tech Res Fndn, Amherst, NY, US; ⁸Brown Med Sch, Providence, RI, US; ⁹Univ of California, San Diego, US; and ¹⁰Univ of North Carolina at Chapel Hill, US
11:30 am 43	Effects of a NRTI, Stavudine, on Insulin Sensitivity and Mitochondrial Function in Muscle of Healthy Adults A Fleischman¹, S Johnsen^1,2, S Johnsen^1,2, D Systrom¹, M Hrovat¹, C Farrar¹, W Frontera^1,3, W Frontera^1,3, K Fitch¹, M Torriani¹, H Cote⁴, and Steven Grinspoon*¹ ¹Massachusetts Gen Hosp, Harvard Med Sch, Boston, US; ²Skejby Univ Hosp, Aarhus, Denmark; ³Spaulding Rehabilitation Hosp and Brigham and Women's Hosp, Boston, MA, US; and ⁴Univ of British Columbia, Vancouver, Canada
11:45 am 44	Significant Sparing of Peripheral Lipoatrophy by HIV Treatment with LPV/r + ZDV/3TC Induction followed by LPV/r Monotherapy Compared with EFV + ZDV/3TC DW Cameron*¹, B da Silva², J Arribas³, F Pulido⁴, H Katner⁵, K Wikstrom², M Woulfe², K Niemi², M King², and G Hanna² ¹Univ of Ottawa at The Ottawa Hosp, Canada; ²Abbott Labs, Abbott Park, IL, US; ³Hosp La Paz, Madrid, Spain; ⁴Hosp Univ Doce de Octubre, Madrid, Spain; and ⁵Mercer Univ Sch of Med, Macon, Georgia, US
12:00 pm 45	Effects of TH9507, a Growth Hormone Releasing Factor Analog, on HIV-associated Abdominal Fat Accumulation: A Multicenter, Double-blind Placebo-controlled Trial with 412 Randomized Patients J Falutz¹, S Allas², K Blot², D Kotler³, M Somero⁴, D Berger⁵, S Brown⁶, G Richmond⁷, J Fessel⁸, and Steven Grinspoon*⁹ ¹Montreal Gen Hosp, McGill Univ Hlth Ctr, Canada; ²Theratechnologies, Inc, Montreal, Canada; ³St Lukes Roosevelt Hosp Ctr, Columbia Univ Coll of Physicians and Surgeons, New York, NY, US; ⁴Palm Springs, CA, US; ⁵Northstar Hlth Care, Chicago, IL, US; ⁶AIDS Res Alliance, West Hollywood, CA, US; ⁷Fort Lauderdale, FL, US; ⁸Kaiser Fndn Res Inst, San Francisco, CA, US; and ⁹Massachusetts Gen Hosp, Boston, US